This result raises an important concern of the general safety of inactivation of ANGPTL3 in patients with coronary artery disease or AMI since ANGPTL3 is considered a novel pharmacological target for the treatment of cardiovascular diseases36,37. Here, ANGPTL3 is linked to coronary artery disorder.